Register Login

Instil Bio Inc (TIL)

  • Event
  • May 18, 2022, 21:03 UTC

(10% Negative) Instil Bio, Inc. (TIL) Announces Delay in patients Trials for cancer Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 9:17 p.m.

    📋 Instil Bio, Inc. (TIL) - Clinical Trial Update

    Filing Date: 2022-05-18

    Accepted: 2022-05-18 17:03:02

    Event Type: Clinical Trial Update

    Event Details:

    Instil Bio Inc (TIL) Announces Clinical Trial Update Instil Bio Inc (TIL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients, populations
    • Diseases/Conditions: cancer
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: the American Society of Gene

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Instil Bio Inc
    • CIK: 0001789769
    • Ticker Symbol: TIL
    • Period End Date: 2022-05-18
    • Document Type: 8-K

Search

News categories